REVIEW

TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer

Wan Hua1,2 · Peter ten Dijke1 · Sarantos Kostidis3 · Martin Giera3 · Marten Hornsveld1

Received: 26 August 2019 / Revised: 10 November 2019 / Accepted: 26 November 2019 / Published online: 10 December 2019
© The Author(s) 2019

Abstract
Metastasis is the most frequent cause of death in cancer patients. Epithelial-to-mesenchymal transition (EMT) is the process in which cells lose epithelial integrity and become motile, a critical step for cancer cell invasion, drug resistance and immune evasion. The transforming growth factor-β (TGFβ) signaling pathway is a major driver of EMT. Increasing evidence demonstrates that metabolic reprogramming is a hallmark of cancer and extensive metabolic changes are observed during EMT. The aim of this review is to summarize and interconnect recent findings that illustrate how changes in glycolysis, mitochondrial, lipid and choline metabolism coincide and functionally contribute to TGFβ-induced EMT. We describe TGFβ signaling is involved in stimulating both glycolysis and mitochondrial respiration. Interestingly, the subsequent metabolic consequences for the redox state and lipid metabolism in cancer cells are found to be in favor of EMT as well. Combined we illustrate that a better understanding of the mechanistic links between TGFβ signaling, cancer metabolism and EMT holds promising strategies for cancer therapy, some of which are already actively being explored in the clinic.

Keywords TGFβ · EMT · Cancer · Signal transduction · Glycolysis · Mitochondrial metabolism · Lipid metabolism · Choline metabolism

Abbreviations
2HG R-2-Hydroxyglutarate
5-FU 5-Fluorouracil
ACC Acetyl-CoA carboxylase
ACLY Adenosine triphosphate citrate lyase
ALL Acute lymphoblastic leukemia
AMPK 5′ AMP-activated protein kinase
AT-RvD1 Aspirin-triggered resolvin D1
CAV1 Caveolin-1
CDKs Cyclin-dependent kinases
CDP Cytidine 5′-diphosphocholine
CHKα Choline kinase
ChREBP Carbohydrate-responsive element-binding protein
CRC Colorectal cancer
E-cadherin Epithelial cadherin
DPYD Dihydropyridine dehydrogenase
EGFR Epidermal growth factor receptor
EMT Epithelial-to-mesenchymal transition
ERK Extracellular signal-regulated kinase
F1,6P2 Fructose-1,6-bisphosphate
F2,6P2 Fructose-2,6-bisphosphate
F6P Fructose-6-phosphate
FASN Fatty acid synthase
FAD Flavin adenine dinucleotide
FH Fumarate hydratase
G6P Glucose-6-phosphate

1 Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands
2 National and Local Joint Engineering Laboratory for Energy Plant Bio-Oil Production and Application, Key Laboratory of Bio-resources and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, People’s Republic of China
3 Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands
GLUT1  Glucose transporter 1  HCC  Hepatocellular carcinoma
GLUT3  Glucose transporter 3  HMGA2  High-mobility group AT-hook 2
GSLs  Glycosphingolipids  HIF  Hypoxia-inducible factor
GST  Glutathione S-transferase  HK2  Hexokinase 2
Background

Increasing evidence shows that the metabolic dysregulation of cancer cells is related to the epithelial-to-mesenchymal transition (EMT) program [1, 2]. In this review, we address the current understanding of metabolic alterations during transforming growth factor-β (TGFβ)-induced EMT and cancer metastasis. In particular, we focus on documented changes in glycolysis, the metabolism of lipids, mitochondrial and choline-associated pathways, and their functional roles.

The TGFβ family is a family of cytokines that act on many different cell types in a pleiotropic manner [3, 4]. TGFβ is secreted by many cell types, and high levels are present in platelets and bone. Three TGFβ isoforms, i.e., TGFβ1, TGFβ2 and TGFβ3, are present in mammals. Differences in their biological functions are predominantly attributed to different spatiotemporal expression patterns [5], and exogenous ligand addition to the three TGF β isoforms has redundant cellular effects. Therefore, in this review, we will refer to TGFβ and not mention a specific isoform unless required. TGFβ signaling is involved in embryonic development and adult tissue homeostasis through the regulation of cell proliferation, survival and differentiation [6, 7]. TGFβ elicits its cellular effects via single transmembrane-spanning TGFβ type I and type II receptors (TGFβR1 and TGFβR2) [8, 9]. Both receptors are endowed with intrinsic serine/threonine kinase activity. TGFβ induces the formation of heteromeric complexes in which the TGFβR2 kinase phosphorylates TGFβR1 [10]. The activated TGFβR1 transduces the signal into the cell by phosphorylating receptor-regulated (R-)SMADs, SMAD2 and SMAD3. These R-SMADs are canonical intracellular effectors of TGFβ. Activated SMAD2 and SMAD3 partner with the SMAD4 transcription factor, and upon their nuclear translocation, heteromeric SMAD complexes orchestrate the regulation of a plethora of targets (Fig. 1). SMAD3 and SMAD4, but not SMAD2, bind directly to DNA [11]. The multifunctionality of TGFβ/SMAD signaling events is mediated in part by cell type-dependent interactions with other DNA-binding transcription factors, co-activators and repressors [3, 12]. Canonical target genes include the extracellular matrix protein...
EMT is characterized by morphological changes in which apical–basal polarized epithelial cells are converted into cells with a mesenchymal spindle-shaped phenotype [30]. EMT is a process of key importance for embryogenesis, and organ development. EMT has been causally linked to cancer invasion and metastasis [31–33] as well as chemotherapy resistance [34] and TGFβ is a pivotal driver of these multistep processes.

Numerous studies have shown that the activation of EMT is fundamental to malignant progression and metastatic dissemination [32, 35]. EMT is defined by the loss of cell–cell adhesion accompanied by the decreased expression of E-cadherin, cytokeratin, ZO-1, laminin-1, occludin and claudin, and the acquisition of a motile and migratory phenotype with the increased expression of N-cadherin, vimentin, and fibronectin, ultimately facilitating the migration of cancer cells [31, 36]. EMT is a dynamic and multistep process closely linked to the interaction between multiple cytokine and inflammatory factors, transcription factors and cellular pathways. Expression of genes that inhibit an epithelial cell phenotype and activate a mesenchymal phenotype involves the transcription factors SNAI1/2, ZEB1/2 and TWIST1/2. In the early stages of EMT, these transcription factors are activated, bind to the E-box in the E-cadherin promoter region and downregulate the expression level of E-cadherin, subsequently reducing epithelial identity [37] (Fig. 1). Increasing evidence demonstrated that EMT is not a binary process, but that partial states exist in which epithelial and mesenchymal markers are co-expressed by cancer cells. These hybrid states are associated with an aggressive phenotype as they confer high plasticity and stemness properties to cancer cells [38–40]. While in most cancer cells, TGFβ-induced EMT is associated with pro-oncogenic response, in pancreatic cancer cells with an intact TGFβ/SMAD4 pathway, it was found associated with apoptosis in a KLF5 repression-dependent manner. In the absence of SMAD4, KLF5 cooperates with SOX4 to promote tumor progression in pancreatic cancer cells [41].

The canonical TGFβ/SMAD pathway plays a pivotal role in mediating EMT. TGFβ-induced SMADs bind to the promoters of SNAI1, TWIST1/2 and ZEB1 and increase their expression [42, 43]. In addition, SMADs can interact and cooperate with SNAI2/1 in a common transcriptional repressive complex that promotes EMT [44]. Epigenetic changes induced by TGFβ/SMAD signaling also contribute to EMT [45, 46]. The non-SMAD signaling pathways of TGFβ can also facilitate epithelial plasticity, sometimes in collaboration with the SMAD pathway [47] (Fig. 1). For example, activation of the PI3K/AKT pathway was required for TGFβ-induced EMT, inhibition of mTOR, a downstream protein kinase of PI3K/AKT signaling, reduced cell migration, adhesion, and invasion that accompany TGFβ-induced EMT of namru murine mammary gland (NMuMG) cells [48, 49]. Moreover, AKT-induced TWIST phosphorylation promoted TGFβ2 transcription and TGFβ receptor activation, and stimulates EMT [50].

It is worth noting that TGFβ-induced EMT can also be a reversible process in cell culture. Upon TGFβ removal, mesenchymal cells can revert back to an epithelial phenotype. Recent findings indicated that a chronic TGFβ treatment induced a stable mesenchymal state in mammary epithelial and breast cancer cells that is different to the reversible EMT upon short-term TGFβ exposure. This stable EMT phenotype was associated with an increased tumor stemness and cancer drug resistance that is susceptible to mTOR inhibition [51].

**Metabolic reprogramming in tumorigenesis and EMT**

Metabolic reprogramming is a hallmark of cancer that contributes to tumorigenesis and disease progression [52]. Cancer cells rewire metabolic pathways to satisfy their
requirement for ATP production, biomass generation and redox balance. The Warburg effect is the most recognized metabolic phenotype observed in cancers. Cancer cells upregulate the uptake of glucose and shift their metabolism from oxidative phosphorylation towards glycolysis, even under aerobic conditions [53, 54]. Although ATP production from glycolysis is very inefficient (2 mol ATP per mol glucose compared to 36 mol ATP per mol glucose in glycolysis and oxidative phosphorylation, respectively), tumors experience advantages in their growth and development from high levels of glycolysis for several reasons. First, high glycolytic rates can increase the tolerance of cancer cells to oxygen fluctuations. Second, as lactate, the final product in glycolytic rates can increase the tolerance of cancer cells to oxygen fluctuations. Third and most importantly, aerobic glycolysis satisfies the demand of rapidly proliferating cancer cells for macromolecular anabolism as large amounts of intermediate metabolites from glycolysis are shunted into different biosynthetic pathways [53, 57, 58].

A recent study found that the Warburg effect contributed to cancer anoikis resistance, which is a prerequisite for tumor metastasis. The shift of ATP generation from oxidative phosphorylation to that from glycolysis protects cancer cells against reactive oxygen species (ROS)-mediated anoikis [59, 60]. As mentioned above, the aberrant activity of oncogenes and tumor suppressors, such as hypoxia-inducible factor 1 (HIF-1), AKT, MYC, p53 and phosphatase and tensin homolog (PTEN), directly affect metabolic pathways, particularly glycolysis [58, 61, 62]. In addition, enhanced glycolysis accompanied by increased lactate fermentation and alleviated mitochondrial respiration protects cancer cells against oxidative stress, favoring tumor metastasis.

The molecular mechanisms of metabolic reprogramming in cancer cells are complex. Metabolic alterations in cancer have been found to be related to the mutation or abnormal expression of oncogenes or tumor suppressors. For instance, KRAS mutations can alter the metabolic flux of pancreatic cancer cells, selectively decompose glucose through the non-redox pentose phosphate pathway, and promote pentose production and nucleic acid synthesis [63]. Aberrant expression of metabolic enzymes is also a key factor for metabolic reprogramming in cancer that is often regulated by certain oncogenes or tumor suppressor genes [64]. For example, PI3K, KRAS and hypoxia-inducible factor (HIF) are responsible for the upregulation of glucose transporter 1 (GLUT1) [65–67]. While it remains to be experimentally tested, it is interesting to take into account that PI3K/AKT and KRAS/MEK/ERK pathways can also be triggered as part of non-canonical TGFβ-signaling and, therefore, might contribute to TGFβ-associated metabolic effects (Fig. 1).

Moreover, metabolic enzyme mutation and dysregulated metabolic enzyme activity can affect cellular metabolism [68]. As cancer cells rely on altered metabolism to support cell proliferation and survival, metabolic pathways are potential therapeutic targets. Recent findings indicate that metabolic changes and EMT are intertwined. While metabolic alterations possibly induce EMT, EMT may also lead to metabolic changes [1, 2]. Notably, a group of 44 metabolic genes named the “mesenchymal metabolic signature” (MMS) genes were found to exhibit increased expression levels in high-grade carcinoma cell lines. Expression of these MMS genes is correlated tightly with mesenchymal markers and was shown to be upregulated upon the activation of EMT by TWIST1 expression in human mammary epithelial cells. Among these genes, dihydroxyribose dehydrogenase (DPYD), an enzyme involved in pyrimidine degradation, was found to be essential for EMT. The role of TGFβ in regulating DPYD remains to be investigated. Importantly, this finding implicates that EMT and metabolic reprogramming are intertwined [69]. Increasing evidence indicates that metabolic alterations influence the EMT process through affecting epigenetic modifications [62]. In this context, the intermediary metabolites of glycolysis and oxidative phosphorylation, such as acetyl-CoA, nicotinamide adenine dinucleotide; NAD+/NADH and flavin adenine dinucleotide (FAD), are used as cofactors to promote epigenetic modifications [62, 70]. While it is clear that EMT and cellular metabolism are interlinked, the knowledge on the role of TGFβ signaling, as well as alternative pathways that can induce EMT, in metabolic reprogramming during EMT is still limited and scattered over various cancer models. In the following sections, we describe the emerging relationships between TGFβ-induced EMT and reprogramming of glycolysis, mitochondrial respiration, lipid and choline metabolism.

**TGFβ signaling stimulates glycolysis**

Aerobic glycolysis enhances the proliferation and survival of tumor cells and provides the basis for tumor cell metastasis and invasion by supplying a large number of metabolic precursors. Simultaneously, the shift from oxidative phosphorylation to glycolysis reduces mitochondrial metabolism, accompanied by decreased ROS production, and was shown to result in anoikis resistance and tumor metastasis [59, 60]. Moreover, the preferential use of aerobic glycolysis leads to the accumulation of lactate in the tumor microenvironment, facilitating the stabilization of HIF-1 and subsequently upregulating the expression of vascular endothelial growth factor (VEGF), resulting in angiogenesis and the stimulation of cell migration [71]. A recent study suggested that extracellular lactate induces SNAI1 and EMT through directly remodeling the extracellular matrix and releasing activated TGFβ1. Furthermore, high extracellular lactate levels can...
contribute to immune evasion, thereby promoting tumor growth and metastasis [72].

Glycolysis has been found to be upregulated in malignant cancer cells. For instance, highly metastatic MDA-MB-231 breast cancer cells have a much higher glycolytic efficiency than nonmetastatic MCF-7 breast cancer cells [55]. Enhanced glycolysis is mainly due to the increased expression or activity of key enzymes. In recent years, tumor targeting by inhibiting the activity of key enzymes in the glycolytic pathway has been explored to decrease proliferation, invasion and metastasis. The levels of glucose transporter 1 (GLUT1) have been demonstrated to increase upon TGFβ stimulation in mesangial cells, breast cancer cells, glioma cells and pancreatic ductal adenocarcinoma [73–76] (Fig. 2). GLUT1 expression was correlated with EMT markers, including E-cadherin and vimentin, and accompanied by increased glucose uptake during TGFβ-induced EMT in breast cancer cells [74]. Furthermore, glucose transporter 3 (GLUT3) also showed higher expression in mesenchymal cells compared to that in epithelial cells among non-small-cell lung carcinoma (NSCLC) cell lines and was also upregulated during TGFβ-induced EMT in H2122 lung cancer cells (Fig. 2).

GLUT3 was identified as a transcriptional target of ZEB1 that facilitates increased cancer cell motility and invasion [77]. TGFβ1 was also shown to upregulate the expression of the gene-encoding hexokinase 2 (HK2), which phosphorylates glucose to produce glucose-6-phosphate (G6P) in the first step in the glycolytic pathway [73] (Fig. 2). HK2 was recently reported to promote pancreatic ductal adenocarcinoma (PDAC) metastasis by mediating lactate production. Moreover, HK2 was also shown to play a key role in the metastatic progression of neuroblastoma [78, 79]. Another enzyme, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), is involved in glycolytic alteration upon TGFβ-induced EMT. One of the rate-limiting steps in glycolysis is the 6-phosphofructo-1-kinase (PFK1) catalyzed conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6P2). PFKFB3 is responsible for the synthesis of fructose-2,6-bisphosphate (F2,6P2), a potent allosteric activator of PFK1, which stimulates glycolysis [80, 81]. TGFβ1 enhanced PFKFB3 expression and stimulated glycolysis in Panc1 pancreatic cells. PFKFB3 silencing inhibited TGFβ-induced invasion in this cell line by repressing the expression of SNAI1 [82]. In addition, PFKFB3 was also upregulated by TGFβ1 in glioma cells, resulting in an increase in fructose 2,6-bisphosphate, glucose uptake, glycolytic flux and lactate production [73] (Fig. 2). Pyruvate kinase M2 (PKM2) is overexpressed in more than 70% of human cancers [83]. This enzyme catalyzes the last step of glycolysis, in which phosphoenolpyruvate (PEP) is dephosphorylated to pyruvate with ATP production. Upon TGFβ-induced EMT of A549 lung adenocarcinoma cells, the expression of PKM2 increases. When levels of PKM2 were decreased by aspirin-triggered resolvin D1 (AT-RvD1), which is well known to be associated with inflammation, TGFβ1-induced EMT was mitigated [84]. Moreover, in colon cancer cells, PKM2 interacts with TGFβ-induced factor homeobox 2 (TGIF2) during TGFβ-induced EMT (Fig. 2). TGIF2 is a transcriptional repressor of TGFβ signaling, and the complex between PKM2 and TGIF2 promotes histone H3K9 deacetylation, resulting in a decrease in E-cadherin transcription [85].
The Warburg effect is characterized by increased glucose uptake and glycolytic activity and the accumulation of lactate in cancer [53]. Interestingly, lactate levels are directly related to cancer metastasis [72, 86]. Cancer cells can metabolize lactate as an energy source and also obtain lactate from cells in the tumor microenvironment, thereby maintaining their acidic environment, leading to apoptosis resistance and increased survival and proliferation [87, 88]. The increased production of lactate occurs during TGFβ-induced EMT [73, 76, 82]. Lactate dehydrogenase type A (LDHA) plays an important role in catalyzing the conversion of pyruvate into lactate. Lactate was shown to promote glioma migration by the TGFβ2-dependent regulation of matrix metalloproteinase-2 (MMP2) [89].

At the end of the glycolytic pathway, pyruvate dehydrogenase kinase (PDK) is an enzyme that inactivates pyruvate dehydrogenase (PDH), which is responsible for converting pyruvate to acetyl-CoA in the mitochondria. Acetyl-CoA then enters the citric acid cycle (TCA) to generate ATP and electron donors, including NADH. In lung cancer cells, downregulation of PDK4 resulted in a shift from glycolysis to oxidative phosphorylation (OXPHOS). TGFβ represses the expression of PDK4 and PDK4 inhibition was sufficient to maintain their acidic environment, leading to apoptosis resistance and increased survival and proliferation [87, 88]. The increased production of lactate occurs during TGFβ-induced EMT [73, 76, 82]. Lactate dehydrogenase type A (LDHA) plays an important role in catalyzing the conversion of pyruvate into lactate. Lactate was shown to promote glioma migration by the TGFβ2-dependent regulation of matrix metalloproteinase-2 (MMP2) [89].

Collectively, these results show that TGFβ stimulates glycolysis while inducing EMT transcriptional programs in a synergistic manner. The transition from oxidative metabolism to glycolysis may benefit tumor metastasis due to the accumulation of cellular building blocks, the rapid generation of ATP and resistance to oxygen fluctuations. The observation that PDK4 is antagonized by TGFβ signaling, however, implicates that flexibility in metabolic routing is a prerequisite for EMT as pyruvate is still allowed, and essential, to shunt into the TCA cycle for EMT to complete.

The TCA cycle is active during EMT

Mitochondria not only are the main energizing organelles in eukaryotes but also play a crucial role in anabolic metabolism by providing intermediates to produce glucose, amino acids, lipids and nucleotides. Therefore, mitochondrial dysfunction is closely related to many diseases, including cancer. Accumulating evidence indicates that disordered mitochondrial metabolism is associated with tumor invasion and metastasis [91–93]. The TCA cycle, one of the main pathways within mitochondria, plays a key role in cell proliferation and provides important intermediates for amino acid, nucleic acid and lipid biosynthesis. Some enzymes involved in the TCA cycle are mutated or dysfunctional in different cancers, i.e. fumarate hydratase (FH), succinate dehydrogenase (SDH), and isocitrate dehydrogenase (IDH). Although these mutations have been directly linked to EMT, the role of TGFβ in regulating TCA intermediates during EMT induction remains to be fully explored [2, 94–99].

FH is a metabolic enzyme responsible for converting fumarate to malate. FH mutations have been discovered in hereditary leiomyomatosis, renal cell cancer, pheochromocytoma and paragangliomas [97, 100]. A recent study demonstrated the relationship between FH and EMT in nasopharyngeal carcinoma (NPC). The chromatin-remodeling factor lymphoid-specific helicase (LSH), the expression of which is controlled by the Epstein–Barr virus-encoded protein LMP1, was increased in NPC. LSH can promote EMT via recruiting the epigenetic silencer factor G9a to repress FH transcription. FH dysfunction resulted in decreased malate and increased α-ketoglutarate (α-KG) levels. Increased α-KG levels altered nuclear factor κ-B kinase α (IKKα)-dependent EMT gene expression by inducing the binding of IKKα to the promoter region of EMT-related genes. This leads to migration and invasion in vitro and tumor growth and metastasis in vivo [101]. Furthermore, fumarate accumulation in FH-deficient renal cancer cells elicited EMT by inhibiting the ten–eleven translocation (TET)-dependent demethylation of the anti-metastatic mRNA miR-200, which suppressed the expression of the EMT transcription factors SNAI2, ZEB1 and ZEB2 [96, 102, 103] (Fig. 3).

Another TCA cycle enzyme linked with EMT is SDH, which is involved in the conversion of succinate to fumarate in the respiratory chain. The SDH complex is composed of four subunits: SDHA (a flavoprotein), SDHB (an iron–sulfur protein), and the two membrane anchor subunits SDHC and SDHD. Mutations in gene-encoding subunits of this enzyme complex have been reported in a subset of human cancers [104, 105]. Decreased SDHB expression has been reported in both human colorectal cancer (CRC) samples and CRC cell lines, and reduced SDHB activity has been correlated with a more advanced clinical lymphatic and distant metastatic phenotype. Further research found that the knockdown of SDHB contributed to cell invasion and migration via EMT by activating the TGFβ signaling pathway through upregulation of the tight junction transcriptional repression complex SNAI1-SMAD3/SMAD4 [106]. The knockdown of SDHB resulted in a hypermethylated epigenome, which was sufficient to trigger EMT in mouse ovarian cancer cells. In addition, SDHB downregulation resulted in succinate accumulation, altered center carbon metabolism and induced mitochondrial dysfunction [94] (Fig. 3).

IDH has also been associated with cancer development and EMT. IDH catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate (α-KG). Furthermore, IDH exists as three isoforms: cytosolic IDH1 and mitochondrial IDH2, which are both NADP+-dependent enzymes,
and mitochondrial IDH3, which is an NAD\(^+\)-dependent enzyme. Mutations in IDH are associated with the development of multiple cancers [107–109]. Mutations in IDH1 and IDH2 lead to the production of R-2-hydroxyglutarate (2HG) from isocitrate instead of α-KG. 2HG and α-KG are highly similar in structure [110], and 2HG is a competitive inhibitor of α-KG-dependent dioxygenases which mainly induces the histone demethylase and DNA demethylase 10–11 TET proteins. The cellular accumulation of 2HG is closely related to the occurrence and development of cancer [111]. The production of 2HG inhibits the activity of α-KG-dependent dioxygenase, leading to impaired histone modification and DNA demethylation [112]. 2HG promotes EMT by increasing histone H3 methylation of the ZEB1 promoter region to upregulate the expression of ZEB1 and downregulate miR-200 expression [95, 113]. Together, ZEB1, miR-200 and TGFβ are part of an autocrine signaling network that stimulates EMT [114]. It might, therefore, be expected that TGFβ signaling synergizes with IDH mutations in the stimulation of invasive cancers (Fig. 3).

Taken together, there is sufficient evidence that TCA cycle metabolites are involved in EMT, but determining the causal relation between metabolite accumulation in one step of the TCA cycle to EMT is challenging. For example, accumulation of fumarate in FH mutant cells is also expected to increase the levels of its precursors such as succinate and α-ketoglutarate. Changes in TCA metabolites can have broad epigenetic effects; therefore, it becomes hard to exactly pinpoint the exact event that triggers EMT and elucidate the mechanism behind this. It is clear, however, that elucidation of TCA metabolite effects in TGFβ-induced EMT holds promising insights into precision-targeting metastatic cancers in the future. Interestingly, TGFβ-induced EMT seems to trigger both glycolysis and mitochondrial activity. This is expected to be a requirement to provide the cell with sufficient ATP to become motile. Indeed, by performing single-cell ATP assays, it was shown that TGFβ-induced EMT results in a spike in ATP levels [115]. Putting ATP production in overdrive comes with a cost, however, as it coincides with increased production of ROS and reduced lipogenesis for which TCA intermediates are required.

**Fig. 3** The TCA cycle is active in TGFβ-induced EMT. The TCA cycle occurs in the matrix of mitochondria and is a key metabolic pathway for providing intermediates to generate glucose, amino acids, lipids, nucleotides and most importantly, ATP. Altered activity of fumarate hydratase (FH), succinate dehydrogenase (SDH), and isocitrate dehydrogenase (IDH) are connected to EMT. The chromatin-remodeling factor lymphoid-specific helicase (LSH) can promote EMT through recruiting the epigenetic silencer factor G9a to suppress FH expression. Furthermore, the accumulation of fumarate also enhances EMT by inhibiting miR-200. Reduced levels of SDHB stimulate EMT by activating the TGFβ signaling pathway. IDH converts isocitrate to α-ketoglutarate but the oncogenic IDHR132H leads to the production of the oncometabolite 2HG. 2HG interferes with chromatin remodeling enzymes and downregulates miR-200 expression via inhibition of TET, subsequently stimulating EMT.

**Redox regulation of TGFβ-mediated EMT**

ROS are highly reactive molecules and the most common forms of cellular ROS are hydrogen peroxide (H\(_2\)O\(_2\)), superoxide (O\(_2^−\)) and hydroxyl radicals (HO\(^*\)). Especially, H\(_2\)O\(_2\) can function as a second messenger by oxidizing target proteins, hereby altering their function or binding partners. The main source of ROS is the ATP-producing electron transport chain in mitochondria. ROS play an important role in cell
signaling and homeostasis [116]. ROS levels in tumor tissues are higher compared to normal tissue and ROS affect many aspects of tumorigenesis [117]. It has been suggested that ROS production is induced by TGFβ to mediate cell proliferation, apoptosis and EMT in cancer [118].

The primary source from which ROS production is stimulated during TGFβ-induced EMT is the mitochondria and found essential for this process [119, 120]. Conversely, it has been demonstrated that mitochondrial thioredoxin (TXN2) repressed TGFβ-induced EMT via different mechanisms. First, TXN interferes with ROS directly as these are important players in the antioxidant pathways that reduce free radicals. Second, TXN antioxidant responses counteract expression of high-mobility group AT-hook 2 (HMGA2), which is a positive regulator of EMT [119, 120]. Furthermore, the mitochondrial enzyme superoxide dismutase 2 (SOD2), which catalyzes O2•− radicals to H2O2 and oxygen, has been found upregulated and required in TGFβ-induced EMT in human oral and esophageal epithelial cell lines [121]. This implicates that the generation of O2•− and subsequent H2O2 by mitochondria is indeed actively stimulated by TGFβ during EMT, but kept within a concentration range that is not harmful for the cell (Fig. 4).

An additional source of TGFβ-induced ROS is NADPH oxidase 4 (NOX4), which belongs to the family of NADPH oxidase enzymes. NOX4 is localized at the cell membrane and NOX4-produced ROS is considered an important redox signal transducer in TGFβ-induced EMT in pancreatic cancer and glioblastoma cells [122–124]. ROS derived from NOX4 oxidize and thereby inhibit protein-tyrosine phosphatase 1B (PTP1B), a known negative regulator of mitogenic signaling and cell migration. Prevention of NOX4-generated ROS by chemical inhibition repressed TGFβ-induced EMT [123]. Additionally, NOX4 stimulates TGFβ-induced p38MAPK activation, which enhances EMT by promoting SNAI1 expression [123]. Others have shown that NOX4 is increased during TGFβ-induced EMT in a SMAD3-dependent manner in breast cancer cells [125] (Fig. 4).

Combined, the generation of ROS from mitochondria and NOX4 in response to TGFβ-induced EMT increases the cellular redox state towards a more oxidative milieu. The consequential redox signaling effects on molecular signal transduction subsequently give rise to an EMT permissive state. Increased redox signaling in renal tubular epithelial cells stimulates phosphorylation of SMAD2 and MAPK, and the expression of mesenchymal markers, which could be counteracted by addition of antioxidants [120]. Similarly, extracellular signal-regulated kinase (ERK) inhibition could repress TGFβ and H2O2-induced EMT, further supporting the important role of ROS in TGFβ-induced EMT via the receptor tyrosine kinase pathways [120]. In accordance, another recent finding indicated H2O2-enhanced TGFβ-mediated EMT via SMAD and MAPK kinase (MEK)/ERK signaling in MCF-10A human mammary epithelial cells [126] (Fig. 4).

Nuclear factor E2-related factor 2 (NRF2) is a critical transcriptional factor that plays a key role in cellular responses to high levels of ROS via stimulating many antioxidant proteins including glutathione S-transferase (GST), NAD(P)H, and quinone oxidoreductase 1 (NQO1) [127]. NRF2 activation contributed to EMT by mediating a decrease in E-cadherin expression and stimulates TGFβ-β-induced SMAD2/3 activity in a pancreatic ductal adenocarcinoma cell line [128]. In addition, NRF2 knockdown
promoted TGF-β1-induced EMT via upregulating SNAIL expression in pulmonary fibrosis [129].

Due to the complex nature of redox signaling on the level of signal transduction and limited experimental tools to study it, the mechanism on how these signals become
Lipid and choline metabolism in TGFβ-induced EMT. Duration lipogenesis, citrate from the TCA cycle is transported into the cytoplasm and cleaved by ATP citrate lyase (ACLY) to acetyl-CoA, which is carboxylated to malonyl-CoA by acetyl-CoA carboxylase (ACC). Subsequently, fatty acid synthase (FASN) catalyzes malonyl-CoA into palmitate, a substrate for triglyceride, phospholipid and cholesterol ester synthesis. Sterol regulatory element-binding proteins (SREBP) and carbohydrate-responsive element-binding protein (ChREBP) are important regulators of ACLY, ACC and FASN transcription. Expression of these enzymes and nuclear factors is repressed during TGFβ-induced EMT. Lipid rafts are formed by cholesterol and sphingolipids, including sphingomyelin (SM), sphingosine-1-phosphate (S1P) and glycosphingolipid (GSL). TGFβ-induced EMT correlates with reduced expression of sphingomyelin synthase (SMS), which converts ceramide to SM. This interferes with EMT induction by TGFβ via inhibition of TGFβR1 and SMAD2 phosphorylation. S1P upregulates matrix metalloproteinase 7 (MMP-7) by stimulating the PI3K/AKT signaling pathway. MMP7 is linked to EMT through the regulation of MMP-7/syndecan-1/TGFβ autocrine loop. Furthermore, TGFβ-signaling decreases Gg4, an important component of GSL required for EMT. ZEB1 promotes the expression of a-series glycosphingolipids including GM3 synthase connecting glycosphingolipid metabolism and epithelial cell adhesion during TGFβ-induced EMT. Choline kinase alpha (CHKα) is a key enzyme in the cytidine 5’-diphosphocholine (CDP)-choline pathway (known as the Kennedy pathway) to generate phosphatidylcholine, an essential component of cell membranes. Abnormal expression and activity of CHKα is associated with tumor metastasis. The EMT activator ZEB1-altered choline metabolism by stimulating CHKα.

Lipid metabolism in TGFβ-induced EMT

Lipids have traditionally been defined as molecules that are insoluble in water and soluble in organic solvents. As this property can be found in a number of biological molecules, a classification system based on chemical and biochemical principles has been established [130]. According to their function, lipids can roughly be divided into storage lipids, such as triglycerides and cholesterol esters, and signaling lipids, such as eicosanoids or steroid hormones. Among the metabolic pathways that are reprogrammed in cancer, lipid metabolism has received less attention than glycolysis and mitochondrial metabolism, but interest in lipid metabolism in cancer has steadily been increasing over the past few years. Abnormal lipid metabolism is closely associated with tumorigenesis; specifically, abnormal lipid metabolism contributes to invasion and metastasis [131, 132].
EMT in NMuMG and HCV29 human normal bladder cells [145]. TGFβ treatment changed the GSL composition and, in particular, downregulated the content of Gg4, which is an important glycosphingolipid that participates in the EMT process. In addition, exogenous supplementation with Gg4 inhibited cell motility and mesenchymal marker expression and elevated the expression of epithelial markers. Furthermore, Gg4 was reported to mediate EMT through its interactions with epithelial molecules such as E-cadherin and β-catenin to maintain epithelial cell membrane organization [146]. The mechanism by which gangliosides regulate EMT may be related to the expression of transcriptional repressors. For instance, ZEB1 upregulates the expression of a-series glycosphingolipids by stimulating the expression of GM3 synthase (St3gal5). Repression of ZEB1 decreased the expression of a-series GSLs and St3gal5, leading to the increased expression of junction-associated proteins such as E-cadherin and plakoglobin [147] (Fig. 5).

Sphingosine-1-phosphate (S1P) is a signaling sphingolipid that is also associated with the EMT process. S1P mediated EMT by regulating the autocrine production of TGFβ1, which contributed to a fibrotic response in A549 lung cancer cells [148]. High levels of serum S1P in hepatocellular carcinoma were found to be associated with poor clinical prognosis [149]. In a recent study, S1P was found to activate PI3K/AKT signaling pathway, resulting in increased MMP-7 expression. MMP-7 regulates the shedding of syndecan-1, a transmembrane heparan sulfate proteoglycan that mediates cell adhesion and migration. The loss of syndecan-1 led to an increase in autocrine TGFβ1, which enabled EMT. Meanwhile, the endogenous expression of TGFβ1 was tightly mediated by MMP-7, thus constituting an MMP-7/syndecan-1/TGFβ1 autocrine loop to mediate hepatocellular carcinoma (HCC) metastasis [150].

Sphingomyelin synthase (SMS), of which there are two isoforms (SMS1/2), are vital enzymes for the production of sphingomyelin (SM) [151, 152]. SM can mediate signaling responses, apoptosis and lipid rafts [153, 154]. The decreased expression of SMS1 was found during TGFβ1-induced EMT in the MDA-MB-231 cell line. In contrast, the overexpression of SMS1-inhibited EMT induced by TGFβ1 and coincides with the upregulation of E-cadherin and downregulation of vimentin [155]. Another study indicated that SMS1 blocks EMT via repressing the expression of TGFβR1 and SMAD2 phosphorylation [155]. Overall, these findings imply that sphingolipids play important roles in EMT induced by TGFβ, and a deeper understanding of the mechanisms by which sphingolipids regulate cancer cell signaling and metastasis will be beneficial to improve cancer treatment.

### Choline metabolism supports EMT

Lipid synthesis is essential for cell growth, proliferation and differentiation, and although many mutations in oncogenes, such as KRAS and MYC, control lipid metabolism [156, 157], few lipid enzymes have been reported to drive tumorigenesis [158]. Choline kinase α (CHKα), a key enzyme involved in choline metabolism, is a notable exception [159]. Aberrant choline metabolism has been observed in multiple cancers. An increasing amount of research has focused on the molecular mechanism underlying abnormal choline metabolism, providing potential targets in cancer therapy [158, 160].

CHKα belongs to the choline kinase protein family, a group of enzymes with a choline kinase/ethanolamine kinase active domain encoded by the CHKA and CHKB genes [159]. CHKα, the first enzyme in the cytidine 5′-diphosphocholine (CDP)-choline pathway (also known as the Kennedy pathway), catalyzes the phosphorylation of free choline using ATP as a phosphate donor to generate phosphocholine. Phosphocholine is a substrate in the synthesis of phosphatidylcholine, the major phospholipid in cell membranes. Numerous studies have confirmed that the abnormal expression and activity of CHKα are apparent in many cancers and correlated with metastasis [161–163].

Although direct regulation of CHKα by TGFβ-signaling has not been reported to date, the expression of EMT transcription factors, including ZEB1, TWIST1 and SNAI1, and the EMT target genes vimentin and N-cadherin were found to be associated with dysfunctional choline metabolism in glioblastoma cells. Also, inhibition of CHKα significantly reduced cell viability, invasiveness, clonogenicity, and the expression of EMT-associated genes [164]. In ovarian cancer cells, downregulation of CHKα impaired aggressiveness and enhanced cellular sensitivity to drug treatment [165]. Furthermore, a combination of CHKA loss and 5-fluorouracil (5-FU) treatment resulted in a larger reduction of cell viability and proliferation in breast cancer cell lines compared to that following 5-FU treatment alone [166]. Overexpression of CHKα induced an aggressive phenotype and increased resistance to 5-FU treatment in MCF-7 breast cancer cells [167]. In addition, increased levels of CHKα significantly reduced the survival of mice with bladder cancer, while the inhibition of CHKα suppressed tumor growth and resulted in a relevant increase in in vivo survival [168]. Further research found that the EGFR/PI3K/AKT pathway was essential for mediating CHKα function in colorectal carcinoma [169]. Inhibition of CHKα by EB-3D, a selective CHKα inhibitor, induced senescence in breast cancer cell lines through stimulation of the 5′ AMP-activated protein kinase (AMPK)-mTOR pathway and impaired breast cancer cell
proliferation, migration, and invasion accompanied by the loss of mesenchymal markers [170]. Due to the increased expression and activity of CHKα in many different cancers described above, CHKα has become a promising target in cancer therapy. Among many CHKα inhibitors under development, RSM-932A is the first inhibitor to be tested in humans in a phase I clinical trial conducted by TCD Pharma (Valladolid, Spain) at two U.S. clinical centers (NCT01213864) in patients with advanced solid tumors.

**Conclusion and perspectives**

EMT is an important stage of cancer development. Cancer cells undergoing EMT acquire invasive characteristics and infiltrate into the surrounding matrix to form a microenvironment that promotes tumor growth and metastasis. As summarized above, increasing evidence supports that EMT is accompanied by complex metabolic rewiring. Changes in metabolites and pathways might be used to improve cancer diagnosis, and the targeting of cancer metabolism to prevent EMT may hold promising new therapeutic strategies for cancer patients.

Some molecules have successfully been applied in clinical therapy to target metabolic pathways. For instance, a group of antisense nucleoside analogs, 5-fluorouracil, gemcitabine, methotrexate and fludarabine, which target different enzymes involved in nucleic acid synthesis, acted as an effective therapy for diverse cancers in patients [171]. Another example is 1-asparaginase, an agent approved to treat acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma via catalyzing the conversion of 1-asparagine to 1-aspartic acid and ammonia, limiting the asparagine available for the tumor [64]. In addition to the successful use of molecules targeting metabolism in the clinic, several metabolic enzymes are evolving as potential candidate targets. Examples include but are not limited to proteins closely linked to TGFβ-induced EMT, such as GLUT1, HK2, PFKFB3, PKM2, LDHA and PDK4, proteins that control glycolysis [172–180], and FASN and ACC, which are involved in lipid synthesis [181–184] (Table 1). Overall, a large number of preclinical research reports provide alternative therapeutic strategies that target EMT and tumor cell migration.

Targeting TGFβ directly during EMT and accompanying metabolic rewiring might provide a potential window for cancer treatment as recent studies have shown that TGFβ inhibition reverses therapy resistance, enhances combinatorial synergy and sensitizes for radiotherapy in cell and mouse models [18]. Systemic treatment with TGFβ inhibitors, however, comes with side effects due to the pleiotropic nature of the pathway and, therefore, is unsuitable or challenging for use in the clinic [18]. In turn, there is a need to find the exact tumor supporting downstream effects of TGFβ signaling to provide promising opportunities for targeting and with this review, we put metabolic reprogramming in the spotlight. However, targeting metabolism comes with a new set of challenges.

Rather than a single metabolite, multiple metabolic pathways are changed simultaneously in tumorigenesis, and combined these metabolic pathways provide potent support for tumor progression. Tumor cells possess high metabolic plasticity in their use of metabolic pathways which also depend on a dynamically changing tumor microenvironment. Normal tissues also depend on the same metabolic pathways for survival and proliferation. These characteristics represent a big challenge for the therapeutic targeting of tumor metabolism. Increased glycolysis as part of the Warburg effect is common in cancer cells but no inhibitors of glycolysis have been approved for therapy, as these also target glycolysis in all healthy cells [171]. In addition, glutamine metabolism can compensate for the decreased glycolysis in tumor cells. Thus, partial and/or combinational targeting might be a more effective strategy as it can be expected that only the highly dependent tumor cells will be affected. Alternatively, instead of focusing on blocking main metabolic routes, targeting synthesis of tumor-specific metabolites that are rare in healthy cells could be more promising. Metabolic changes during EMT are interesting in this respect as EMT is an almost unique property of cancer cells in the adult body, with small cell populations during wound healing and angiogenesis as exceptions.

Finally, next to metabolic changes in cancer cells during TGFβ-induced EMT, the metabolic microenvironment will be affected. This not only contributes to promote tumor progression and therapy resistance, but also connects to immune suppression. Nutrient deficiency caused by hyperactive tumor cell metabolism and metabolites released from tumor cells into the microenvironment affect immune cell function and facilitate immune suppression [185, 186]. Increased glycolysis in tumor cells results in low glucose levels in the microenvironment and is linked to inhibition of glycolysis in tumor-infiltrating lymphocytes [187]. Additionally, accumulation of lactate in tumor microenvironment impairs proliferation and mobility of cytotoxic T lymphocytes and natural killer (NK) cells [56]. Conclusion, this review illustrates that the understanding and targeting of TGFβ-induced metabolic changes during EMT is emerging and provides basis for novel cancer treatments including targeted and immune therapy.
Acknowledgements
We thank our colleagues for valuable discussion.

Author contributions
All authors contributed to writing the review. All authors read and approved the final manuscript.

Funding
Our research on metabolic reprogramming in cancer is supported by CGC.nl and by Chinese Scholarship Council.

Compliance with ethical standards

Conflict of interest
The authors declare that they have no competing interests.

Consent for publication
All authors read and approved the final manuscript.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Morandi A, Taddei ML, Chiarugi P, Giannoni E (2017) Targeting the metabolic reprogramming that controls epithelial-to-mesenchymal transition in aggressive tumors. Front Oncol. https://doi.org/10.3389/fonc.2017.00040
2. Sciacovelli M, Frezza C (2017) Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J 284(19):3132–3144. https://doi.org/10.1111/febs.14090
3. David CJ, Massague J (2018) Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol 19(7):419–435. https://doi.org/10.1038/s41580-018-0007-0
4. Zhang YE (2018) Mechanistic insight into contextual TGF-β signaling. Curr Opin Cell Biol 51:1–7. https://doi.org/10.1016/j.ceb.2017.10.001
5. Gatherer D, Ten Dijke P, Baird DT, Akhurst RJ (1990) Expression of TGF-β isoforms during first trimester human embryogenesis. Development (Cambridge, England) 110(2):445–460
6. Massagué J (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol 13(10):616–630. https://doi.org/10.1038/nrm3434

Table 1

| Target | Description | Agent | Development stage | Indication | References |
|--------|-------------|-------|-------------------|------------|------------|
| GLUT1  | Glycolysis: glucose transportation | WZB117, BAY-876 | Preclinical data | Anticancer activity in vitro and in vivo | [169, 170] |
| HK2    | Glycolysis: phosphorylation of glucose to glucose-6-phosphate (G6P) | 2-Deoxyglucose, lonidamine | Preclinical and clinical data | Anticancer activity in vitro and in vivo; Lonidamine has been tested in phase 3 clinical trial (NCT00435448) | [171, 172] |
| PFKFB3 | Glycolysis: activator of PFK1, promote glycolysis | ACT-PFK158 | Preclinical and clinical data | Anticancer activity in vitro and in vivo, has been tested in phase 1 clinical trial (NCT02044861) | [173] |
| PKM2   | Glycolysis: dephosphorylation of phosphoenolpyruvate to pyruvate | TLN-232 | Preclinical and clinical data | Anticancer activity in vitro and in vivo | [174, 175] |
| LDHA   | Glycolysis: conversion of pyruvate to lactate | FX11, GNE-140 | Preclinical data | Anticancer activity in vitro and in vivo | [169, 176] |
| PDK4   | Glycolysis: a negative regulator of PDH | Dichloroacetate | Preclinical and clinical data | Anticancer activity in vitro and in vivo, has been tested in phase 2 clinical trial (NCT00735332) | [177] |
| FASN   | Lipogenesis: synthesis of palmitate from malonyl-CoA | TVB–2640 | Preclinical and clinical data | Anticancer activity in vitro and in vivo, has been tested in phase 2 clinical trial (NCT01386632) | [178–180] |
| ACC    | Lipogenesis: carboxylation of acetyl-CoA to malonyl-CoA | GS-0976 | Preclinical and clinical data | Decreased hepatic steatosis, has been tested in phase 2 clinical trial (NCT02856555) | [178, 179, 181] |

*Clinical trial information was obtained from https://clinicaltrials.gov/
7. Akhurst RJ, Hata A (2012) Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 11(10):790–811. https://doi.org/10.1038/nrd3810
8. Derynck R, Budi EH (2019) Specificity, versatility, and control of TGF-β family signaling. Sci Signal. https://doi.org/10.1126/scisignal.aav5183
9. Heldin CH, Moustakas A (2016) Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a022053
10. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J (2000) TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309. https://doi.org/10.1016/S0092-8674(00)01245-2
11. Colak S, Ten Dijke P (2017) Targeting TGF-β family signaling in the control of cell proliferation and survival. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a022053
12. Massague J (2008) TGFβ in cancer. Cell 134(1):215–230. https://doi.org/10.1016/j.cell.2008.07.001
13. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuvel RJ, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thompson CA, Massague J (2016) Transcriptional control by the SMADs. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a022053
14. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thompson CA, Massague J (2016) Transcriptional control by the SMADs. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a022053
15. Katsuno Y, Lamouille S, Derynck R (2013) TGFβ-activator inhibitor-type 1 gene. Embo J 17(11):3091–3100. https://doi.org/10.1038/emboj.2013.194
16. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Massague J (2013) Analysis of TGFβ family signaling. Sci Signal. https://doi.org/10.1126/scisignal.2002315
17. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 421(6920):577–584. https://doi.org/10.1038/nature01328
18. Colak S, Ten Dijke P (2017) Targeting TGF-β family signaling in cancer. Trends Cancer 3(1):63–66. https://doi.org/10.1016/j.trecancer.2016.11.008
19. Zhang Y, Alexander PB, Wang XF (2017) TGF-β family signaling in the control of cell proliferation and survival. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a022053
20. Massague J, Blain SW, Lo RS (2000) TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309. https://doi.org/10.1016/S0092-8674(00)01245-2
21. Massague J, Blain SW, Lo RS (2000) TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309. https://doi.org/10.1016/S0092-8674(00)01245-2
22. Schuster N, Kriegstein L (2002) Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 307(1):1–14. https://doi.org/10.1007/s00441-001-0479-6
23. Ten Dijke P, Goumans MJ, Itoh F, Itoh S (2002) Regulation of cell proliferation by Smad proteins. J Cell Physiol 191(1):1–16. https://doi.org/10.1002/jcp.10066
24. Liu F, Matsuura I (2005) Inhibition of Smad antiproliferative function by CDK, phosphorylation. Cell Cycle (Georgetown, Tex) 4(1):63–66. https://doi.org/10.4161/cc.4.1.1366
25. Pardali K, Moustakas A (2007) Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775(1):21–62. https://doi.org/10.1016/j.bbadis.2006.06.004
26. Drabsch Y, ten Dijke P (2012) TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31(3–4):553–568. https://doi.org/10.1007/s10555-012-9375-7
27. Inman GJ (2011) Switching TGFβ from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 21(1):93–99. https://doi.org/10.1016/j.gde.2010.12.004
28. Lu J, Guo H, Treikatkarmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D (2009) 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial–mesenchymal transition. Cancer Cell 16(3):195–207. https://doi.org/10.1016/j.ccr.2009.08.010
29. Yeh HW, Hsu EC, Lee SS, Lang YD, Lin YC, Chang CY, Lee SY, Gu DL, Shih JH, Ho CM, Chen CF, Chen CT, Tu PH, Cheng CF, Chen RH, Yang RB, Jou YS (2018) PSPC1 mediates TGF-β1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis. Nat Cell Biol 20(4):479–491. https://doi.org/10.1038/s41556-018-0062-y
30. Derynck R, Weinberg RA (2019) EMT and cancer: more than meets the eye. Dev Cell 49(3):313–316. https://doi.org/10.1016/j.devcel.2019.04.026
31. Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal transition. J Clin Invest 119(6):1420–1428. https://doi.org/10.1172/JCI39104
32. Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. https://doi.org/10.1038/nrc8222
33. Yang J, Weinberg RA (2008) Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14(6):818–829. https://doi.org/10.1016/j.devcel.2008.05.009
34. van Staalduinen J, Baker D, Ten Dijke P, van Dam H (2018) Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. https://doi.org/10.1038/s41388-018-0378-x
35. Savagner P (2010) The epithelial–mesenchymal transition (EMT) phenomenon. Ann Oncol. https://doi.org/10.1093/annonc/mdq292
36. Lamouille S, Yu J, Derynck R (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196. https://doi.org/10.1038/nrm3755
37. Tsubakihara Y, Moustakas A (2018) Epithelial–mesenchymal transition. J Cell Sci 131(3–4):553–568. https://doi.org/10.1016/j.jcb.2018.12.001
38. Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29(3):212–226. https://doi.org/10.1016/j.tcb.2018.12.001
39. Santamaria PG, Moreno-Bueno G, Cano A (2019) Contribution of epithelial plasticity to therapy resistance. J Clin Med 8(5):89. https://doi.org/10.3390/jcm8050089
40. Xue Y, Cui J, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue CA, Massague J (2016) TGF-β tumor suppression through a lethal EMT. Cell 164(5):1015–1030. https://doi.org/10.1016/j.cell.2016.01.009
41. Tsukahara Y, Moustakas A (2018) Epithelial–mesenchymal transition and metastasis under the control of transforming growth factor β. Int J Mol Sci 19(11):3672. https://doi.org/10.3390/ijms19113672
42. Tsukahara Y, Moustakas A (2018) Epithelial–mesenchymal transition inducing metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. 2117
43. Du D, Katsuno Y, Meyer D, Budi EH, Chen SH, Koeppen J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF, Fuje J (2009) A SNA1L-SMAD3/4 transcriptional repressor complex promotes TGF-β-mediated epithelial–mesenchymal transition. Nat Cell Biol 11(8):943–950. https://doi.org/10.1038/ncb1905

44. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF, Fuje J (2009) A SNA1L-SMAD3/4 transcriptional repressor complex promotes TGF-β-mediated epithelial–mesenchymal transition. Nat Cell Biol 11(8):943–950. https://doi.org/10.1038/ncb1905

45. Derynck R, Muthusamy BP, Saeteurn KY (2014) Signaling pathway cooperation in TGF-β-induced epithelial–mesenchymal transition. Curr Opin Cell Biol 31:56–66. https://doi.org/10.1016/j.ceb.2014.09.001

46. Lamouille S, Derynck R (2007) Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178(3):437–451. https://doi.org/10.1083/jcb.200611146

47. Xu W, Yang Z, Lu N (2015) A new role for the PI3K/Akt signaling pathway in the epithelial–mesenchymal transition. Cell Adhes Migr 9(4):317–324. https://doi.org/10.4161/cam.91890.2015.1016686

48. Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.01.058

49. Xu W, Yang Z, Lu N (2015) A new role for the PI3K/Akt signaling pathway in the epithelial–mesenchymal transition. Cell Adhes Migr 9(4):317–324. https://doi.org/10.4161/cam.91890.2015.1016686

50. Katsuno Y, Meyer D, Budi EH, Chen SH, Koeppen J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF, Fuje J (2009) A SNA1L-SMAD3/4 transcriptional repressor complex promotes TGF-β-mediated epithelial–mesenchymal transition. Nat Cell Biol 11(8):943–950. https://doi.org/10.1038/ncb1905

51. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.015

52. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 324(5930):1029–1033. https://doi.org/10.1126/science.1160809

53. Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41(3):211–218. https://doi.org/10.1016/j.tib.2015.12.001

54. Gatesy RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899. https://doi.org/10.1038/nrc1478

55. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mitterer M, Ritter U, Schmid M, Blank C, Dettmer K, Ofner P, Hoffmann P, Valenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Bernburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24(5):657–671. https://doi.org/10.1016/j.cmet.2016.08.011

56. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13(6):472–482. https://doi.org/10.1016/j.ccr.2008.05.005

57. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85–95. https://doi.org/10.1038/nrc2981

58. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, Lu J (2012) Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol 32(10):1893–1907. https://doi.org/10.1128/MCB.06248-11

59. Lu J, Tan M, Cai Q (2015) The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 356(2):156–164. https://doi.org/10.1016/j.canlet.2014.04.001

60. Agathocleous M, Harris WA (2013) Metabolism in physiological tumor proliferation and differentiation. Trends Cell Biol 23(10):484–492. https://doi.org/10.1016/j.tcb.2013.05.004

61. Li L, Li W (2015) Epithelial–mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol Ther 150:33–46. https://doi.org/10.1016/j.pharmthera.2015.01.004

62. Ying H, Kimmelgale Alec C, Lyssiotis Costas A, Hua S, Chu Gerald C, Fletcher-Sananikone E, Locasale Jason W, Son J, Zhang H, Coloff Jonathan L, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik J-J, Lim C, Guimaraes Alexander R, Martin Eric S, Chang J, Hezel A, Perry Samuel R, Hu J, Gan B, Xiao Y, Asara John M, Weissleder R, Wang YA, Chin L, Cantley Lewis C, DePinho Ronald A (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anaerobic glucose metabolism. Cell 149(3):656–670. https://doi.org/10.1016/j.cell.2012.01.058

63. Cunnihill JL, Grossman EA, Nomura DK (2018) Cancer metabolism: current understanding and therapies. Chem Rev 118(14):6893–6923. https://doi.org/10.1021/acs.chemrev.7b00775

64. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, NY) 325(5947):1555–1559. https://doi.org/10.1126/science.1174229

65. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20(1):51–56. https://doi.org/10.1016/j.gde.2009.10.009

66. Wieman HL, Woford JA, Rathmell JC, Margolis B (2007) Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Cell Biol 18(4):1437–1446. https://doi.org/10.1091/mcb.e06-07-0593

67. Vander Heiden MG, DeBerardinis RJ (2017) Understanding the intersections between metabolism and cancer biology. Cell 168(4):657–669. https://doi.org/10.1016/j.cell.2016.12.039

68. Shaul YD, Freinkman E, Comb WC, Cantor JR, Tam WL, Thiru P, Kim D, Kanarek N, Pacold ME, Chen WW, Bierie B, Possemato R, Reinhardt F, Weinberg RA, Yaffe MB, Sabatini DM (2014) Dihydropyrimidine accumulation is required for the epithelial–mesenchymal transition. Cell 158(5):1094–1109. https://doi.org/10.1016/j.cell.2014.07.032

69. Sabari BR, Zhang D, Allis CD, Zhao Y (2017) Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol 18(2):90–101. https://doi.org/10.1038/nrm.2016.140

70. Goodwin ML, Gladden LB, Nijsten MW, Jones KB (2014) Lactate and cancer: revisiting the Warburg effect in an era of lactate shuttling. Front Nutr 1:27. https://doi.org/10.3389/fnut.2014.00027

71. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andresen R,
Krause SW, Kreutz M (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9):3812–3819. https://doi.org/10.1182/blood-2006-07-035972

73. Rodriguez-Garcia A, Samso P, Fontova P, Simon-Molas H, Manzano A, Castano E, Rosa JL, Martinez-Outshoorn U, Ventura F, Navarro-Sabate A, Bartrons R (2017) TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells. FEBS J 284(20):3437–3454. https://doi.org/10.1111/febs.14201

74. Li W, Wei Z, Liu Y, Lin H, Ren R, Tang Y (2010) Increased 18F-FDG uptake and expression of Glut1 in the EMT transformed breast cancer cells induced by TGF-β. Neoplasma 57(3):234–240. https://doi.org/10.4149/neop_2010_03_234

75. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R (1999) TGF-β1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 55(5):1704–1712. https://doi.org/10.1046/j.1523-1755.1999.00438.x

76. Liu M, Quek LE, Sultani G, Turner N (2016) Epithelial–mesenchymal transition induction is associated with augmented glucose uptake and lactate production in pancreatic ductal adenocarcinoma. Cancer Metab 4:19. https://doi.org/10.1186/s40170-016-0160-x

77. Masin M, Vazquez J, Rossi S, Groeneveld S, Samson N, Schwalie WP, Gomis R, Delorenzi M, Cervera E, Morris D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Wyns S, Vinganti RA, Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley B, Pourtois G, Carmeliet P (2013) Role of PFKFB3-driven glycolysis in epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Cancer Metab 2:11. https://doi.org/10.1186/2049-3002-2-11

78. Botzer LE, Maman S, Sagi-Assif O, Meshel T, Nevo I, Yron I, Anderson M, Marayati R, Moffitt R, Yeh JJ (2017) Hexokinase 2 is a determinant of neuroblastoma metastasis. Br J Cancer 114(7):759–766. https://doi.org/10.1038/bjc.2016.26

79. Anderson M, Marayati R, Moffitt R, Yeh JJ (2017) Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 8(34):35608–35694. https://doi.org/10.18632/oncotarget.19760

80. De Bock KG, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquiere B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembusyer B, Breuools K, Welte J, Geudens I, Segura I, Cruys B, Bifari F, Decimo I, Blanco R, Wynn S, Vangiandertuel J, Rocha S, Collins RT, Munck S, Daelmans M, Inamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hoffens J, Frapis P, Telang S, Deberardinis RJ, Schoonjans L, Vinckier S, Cheynel J, Gerhardt H, Wexherman M, Agalliu D, Schauer W, Collard R, Jourdann P (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154(3):651–663. https://doi.org/10.1016/j.cell.2013.06.037

81. Van Schaftingen E, Lederer B, Bartrons R, Hers HG (1982) A gene expression and glycolysis in glioblastoma cells. FEBS J 284(20):3437–3454. https://doi.org/10.1111/febs.14201

82. Yalcin A, Solakoglu TH, Ozcan SC, Guzel S, Peker S, Celikler S, Balaban BD, Sevinc E, Gurpinar Y, Chesney JA (2017) Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial–mesenchymal transition and drug resistance in tumor cells. Cancer Metab 2(1):20. https://doi.org/10.1186/2049-3002-2-20

83. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84(6):1014–1020. https://doi.org/10.1016/j.ygeno.2004.08.010

84. Liu Y, Yuan X, Li W, Cao Q, Shu Y (2016) Aspirin-triggered resolvin D1 inhibits TGF-β1-induced EMТ through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely associated to cytotoxic stress. Int J Mol Med 38(4):1235–1242. https://doi.org/10.3892/ijmm.2016.2721
pheochromocytomas and paragangliomas. Hum Mol Genet 23(9):2440–2446. https://doi.org/10.1093/hmg/ddu639

98. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Mysiordek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard CW 3rd, Corneliess CJ, Devilee P, Devlin B (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (New York, NY) 287(5454):848–851. https://doi.org/10.1126/science.287.5454.848

99. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Van Kien PK, Corvol P, Plouin PF, Jeunemaitre X (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant pheochromocytomas. Cancer Res 63(17):5615–5621

100. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kellison D, Leigh I, Gorman P, Lamhlu M, Rahman S, Roylanse RR, Olpin S, Bevan S, Barker K, Hearsel N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Villikki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA, Multiple Leiomyoma C (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30(4):406–410. https://doi.org/10.1038/ng849

101. He X, Yan B, Liu J, Jia L, Wai XN, Tang CE, Luo D, Tan T, Jiang Y, Shi Y, Liu Y, Xiao D, Chen L, Liu S, Mao C, Yin G, Cheng Y, Fan J, Cao Y, Muegge K, Tao Y (2016) Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res 76(19):5743–5755. https://doi.org/10.1158/0008-5472.CAN-16-0268

102. De Craene B, Berx G (2013) Regulatory networks defining epithelial–mesenchymal transition and cell populations defined by differential expression in epithelial–mesenchymal transition and is associated with distant metastasis in colorectal cancer. Sci Rep 6:36289. https://doi.org/10.1038/srep36289

103. Sciacovelli M, Frezza C (2017) Fumarate drives EMT in renal cancer. Cell Death Differ 24(1):1–2. https://doi.org/10.1038/cdd.2016.137

104. Letouze E, Martinelli C, Loriot C, Burnichon I, Tomlinson I (2011) SDH mutations in extra-adrenal pheochromocytomas and paragangliomas. Hum Mol Genet 20(17):3577–3585. https://doi.org/10.1093/hmg/ddr156

105. Bardella C, Pollard PL, Tomlinson I (2011) SDH mutations in cancer. Biochim Biophys Acta 1807(11):1432–1433. https://doi.org/10.1016/j.bbabio.2011.07.003

106. Wang H, Chen Y, Wu G (2016) SDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4. Transl Oncol 9(6):512–520. https://doi.org/10.1016/j.trano.2016.09.009

107. Waitkus MS, Diplas BH, Yan H (2016) Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol 18(1):16–26. https://doi.org/10.1093/neuonc/nov136

108. Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N (2016) Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov 6(7):727–739. https://doi.org/10.1158/2159-8290.CD-15-1442

109. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WT, Zhao F, Medeiros BC, Tyvoll DA, Majeti R (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21(2):178–184. https://doi.org/10.1038/nm.3788

110. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17–30. https://doi.org/10.1016/j.ccr.2010.12.014

111. Lu C, Ward PS, Kapoor GS, Rohde D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O’Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390):474–478. https://doi.org/10.1038/nature10860

112. Lag D, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liuam LI, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739–744. https://doi.org/10.1038/nature08617

113. Colvin H, Nishida N, Konno M, Haraguchi N, Takahashi H, Nishimura H, Hata T, Kawamoto K, Asai A, Tsunekuni K, Kosuki J, Mizushima T, Sato T, Doki Y, Mori M, Ishi H (2016) Oncometabolite D-2-hydroxyglutarate directly induces epithelial–mesenchymal transition and is associated with distant metastasis in colorectal cancer. Sci Rep 6:36289. https://doi.org/10.1038/srep36289

114. Hara SY, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim Y, Lindeman GI, Shannan MF, Drew PA, Khaew-Goodall Y, Goodall GJ (2011) An autocrine TGF-β/β-ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 22(10):1686–1698. https://doi.org/10.1091/mbc.E11-02-0103

115. Zarad S, Arumugam R, Hershman H, Phelps ME, Levine RD (2014) Surprisal analysis characterizes the free energy time course of cancer cells undergoing epithelial-to-mesenchymal transition. Proc Natl Acad Sci USA 111(36):13235–13240. https://doi.org/10.1073/pnas.1414714111

116. Chio IIC, Tuveson DA (2017) ROS in cancer: the burning question. Trends Mol Med 23(5):411–429. https://doi.org/10.1016/j.molmed.2017.03.004

117. Hornsveld M, Dansen TB (2016) The hallmarks of cancer from a redox perspective. Antioxid Redox Signal 25(6):300–325. https://doi.org/10.1089/ars.2015.6580

118. Liu RM, Desai LP (2015) Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol 6:565–577. https://doi.org/10.1016/j.redox.2015.09.009

119. Ishikawa F, Kaneko E, Sugimoto T, Ishijima T, Yokami M, Yuasa A, Sampei R, Mori K, Nose K, Shibanuma M (2014) A mitochondrial thioredoxin-sensitive mechanism regulates TGF-β-mediated gene expression associated with epithelial–mesenchymal transition. Biochem Biophys Res Commun 443(3):821–827. https://doi.org/10.1016/j.bbrc.2013.12.050

120. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, UH ST, Lee HB (2005) Role of reactive oxygen species in TGF-β1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 16(3):667–675. https://doi.org/10.1681/ASN.2004050425

121. Kinugasa H, Whelan KA, Tanaka K, Natsukazaka M, Long A, Guo A, Chang S, Kagaawa S, Srinivasan S, Guha M, Yamamoto K, St Clair DK, Avadhanji NG, Diehl JA, Nakagawa H (2015) Mitochondrial SOD2 regulates epithelial–mesenchymal transition and cell populations defined by differential...
CD44 expression. Oncogene 34(41):5229–5239. https://doi.org/10.1038/onc.2014.449

122. Lambeth JD (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4(3):181–189. https://doi.org/10.1038/nri1312

123. Hiraga R, Kato M, Miyagawa S, Kamata T (2013) Nox4-derived ROS signaling contributes to TGF-β-induced epithelial–mesenchymal transition in pancreatic cancer cells. Anticancer Res 33(10):4431–4438

124. Mondol AS, Tonks NK, Kamata T (2014) Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C. Free Radic Biol Med 67:285–291. https://doi.org/10.1016/j.freeradbiomed.2013.11.005

125. Boudreau HE, Casterline BW, Rada B, Korzeniowska A, Leto TL, Singh R, Yadav V, Kumar S, Saini N (2015) MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep 5:17454. https://doi.org/10.1038/srep17454

126. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8(4):311–321. https://doi.org/10.1016/j.ccr.2005.09.008

127. Beckers A, Organe S, Timmermans L, Scheps K, Peeters A, Brusselmans K, Verhoeven G, Swinnen JV (2007) Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 67(17):8180–8187. https://doi.org/10.1158/0008-5472.Can-07-0389

128. Yang L, Zhang F, Wang X, Tsai Y, Chuang KH, Keng PC, Lee SO, Chen Y (2016) A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer. Oncotarget 7(34):55543–55554. https://doi.org/10.18632/oncotarget.10837

129. Jiang L, Xiao L, Sugira H, Huang X, Ali A, Kuro-o M, Deberardinis RJ, Boothman DA (2015) Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition. Oncogene 34(30):3908–3916. https://doi.org/10.1038/onc.2014.321

130. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9(2):139–150. https://doi.org/10.1038/nrnm2329

131. Santos CR, Schulze A, Leto TL, Singh R, Yadav V, Kumar S, Saini N (2015) Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 106(18):7461–7466. https://doi.org/10.1073/pnas.0902368106

132. Santos CR, Schulze A, Leto TL, Singh R, Yadav V, Kumar S, Saini N (2015) Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 106(18):7461–7466. https://doi.org/10.1073/pnas.0902368106

133. Ogreston B (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 18(1):33–50. https://doi.org/10.1038/nrc.2017.96

134. Guan F, Handa K, Hakomori SI (2009) Local inhibition of lysophosphatidylcholine and sphingomyelin selectively in cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep 5:17454. https://doi.org/10.1038/srep17454

135. Mathow D, Chessa F, Rabionet M, Kaden S, Jennemann R, Sandhoff R, Grone HJ, Feuerborn A (2015) Zeb1 affects epithelial cell adhesion by diverting glycosphingolipid metabolism. EMBO Rep 16(3):321–331. https://doi.org/10.15252/embr.201449333

136. Menges R, Navarro R, Juan G, Peiro T, Serrano A, Morcillo E, Cortijo J (2012) Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial-to-mesenchymal transition. Thorax 67(2):147–156. https://doi.org/10.1136/thoraxjnl-2011-200026

137. Wang C, Mao J, Redfield S, Mo Y, Lager JM, Zhou X (2014) Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues. Exp Mol Pathol 97(2):259–265. https://doi.org/10.1016/j.yexmp.2014.07.013

138. Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang Y, Feng T, Wu J, Liu X (2016) Sphingosine-1-phosphate induced epithelial–mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-β autocrine loop. Oncotarget 7(39):56324–63337. https://doi.org/10.18632/oncotarget.11450

139. Huitjema K, van den Dikkenberg J, Brouwers JF, Holthuis JC (2004) Identification of a family of animal sphingomyelin synthases. EMBO J 23(1):33–44. https://doi.org/10.1093/emboj/6700034

140. Yamaoka S, Miyaji M, Kitano T, Umehara H, Okazaki T (2004) Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective cells through the fatty acid receptor CD36. Nature 541(7635):41–45. https://doi.org/10.1038/nature20791

141. Singh R, Yadav V, Kumar S, Saini N (2015) Sphingosine-1-phosphate and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med 53(7):1489–1499. https://doi.org/10.1016/j.freeradbiomed.2012.06.016

142. Arfmann-Knubel S, Struck B, Genrich G, Helm O, Sipos B, Sebens S, Schafer H (2015) The crossstalk between Nrf2 and TGF-β1 in the epithelial–mesenchymal transition of pancreatic duct epithelial cells. PLoS One 10(7):e0132978. https://doi.org/10.1371/journal.pone.0132978

143. Zhou W, Mo X, Cui W, Zhang Z, Li D, Li L, Xu L, Yao H, Gao J (2016) Nrf2 inhibits epithelial–mesenchymal transition by suppressing snail expression during pulmonary fibrosis. Sci Rep 6:38646. https://doi.org/10.1038/srep38646

144. Iizuka D, Sasaki M, Barcellos-Hof M, Kamiya K (2017) Hydrogen peroxide enhances TGFβ-mediated epithelial-to-mesenchymal transition in human mammary epithelial MCF-10A cells. Anticancer Res 37(3):987–995. https://doi.org/10.21873/anticancer.11408

145. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610–2623. https://doi.org/10.1111/febs.12030

146. Arolfetto R, Roberts LR, Chan C (2015) Elevated free fatty acid uptake via CD36 promotes epithelial–mesenchymal transition in hepatocellular carcinoma. Sci Rep 5:14752. https://doi.org/10.1038/srep14752

147. Tao W, Zhao Y, Fuente S, Sijacic P, Rich X, Levental I, Chang JT (2016) Motility and stem cell properties induced by the epithelial-mesenchymal transition require destabilization of lipid rafts. Oncotarget 7(32):51553. https://doi.org/10.18632/oncotarget.9928

148. Li J, Dong L, Wei D, Wang X, Zhang S, Li H (2014) Fatty acid synthase mediates the epithelial–mesenchymal transition of breast cancer cells. Int J Biol Sci 10(2):171

149. Nath A, L I, Roberts LR, Chan C (2015) Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep 5:14752. https://doi.org/10.1038/srep14752

150. Nath A, Chan C (2016) Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci Rep 6:18669. https://doi.org/10.1038/srep18669

151. Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A, Hueto JA, Bescos C, Di Croce L, Benitah SA (2017) Targeting metastasis-initiating...
lymphoid cells. J Biol Chem 279(18):18688–18693. https://doi.org/10.1074/jbc.M401205200

153. Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science (New York, NY) 327(5961):46–50. https://doi.org/10.1126/science.1174621

154. Taniguchi M, Okazaki T (2014) The role of sphingomyelin and sphingomyelin syntheses in cell death, proliferation and migration—from cell and animal models to human disorders. Biochim Biophys Acta (BBA) Mol Cell Biol Lipids 1841(5):692–703. https://doi.org/10.1016/j.bbalip.2013.12.003

155. Liu S, Hou H, Zhang P, Wu Y, He X, Li H, Yan N (2018) Sphingomyelin synthesis regulates the epithelial-to-mesenchymal transition mediated by the TGF-β/Smad pathway in MDA-MB-231 cells. Mol Med Rep. https://doi.org/10.3892/mmr.2018.9722

156. Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, Zare RN, Felsher DW (2017) Oncogenic KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci USA 114(17):4300–4305. https://doi.org/10.1073/pnas.1617709114

157. Edmunds LR, Sharma L, Kang A, Lu J, Vockley J, Basu S, Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science (New York, NY) 327(5961):46–50. https://doi.org/10.1126/science.1174621

158. Arlauckas SP, Popov AV, Delikatny EJ (2016) Choline kinase α—putting the ChoK-hold on tumor metabolism. Prog Lipid Res 63:28–40. https://doi.org/10.1016/j.plipres.2016.03.005

159. Aoyama C, Liao H, Ishidate K (2004) Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43(3):266–281. https://doi.org/10.1016/j.plipres.2003.12.001

160. Huang C, Freter C (2015) Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci 16(1):924–949. https://doi.org/10.3390/ijms16010924

161. Bertilsson H, Tessem MB, Flathberg A, Viset T, Gribbestad I, Ramirez de Molina V, Cejas P, Ozu C, Le C, Sanchez JJ, Lacal JC (2009) A critical role for choline kinase-α in the aggressiveness of bladder carcinomas. Oncogene 28(26):2425–2435. https://doi.org/10.1038/onc.2009.91

162. Ramirez de Molina A, Sanchez J, Rosell R, Lacal JC (2002) Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 21(18):3462–3468. https://doi.org/10.1038/onc.2009.91

163. Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14(1):11–31. https://doi.org/10.1038/nrclin.2016.60

164. Koch K, Hartmann R, Schroter R, Suwala AK, Maciaczyk J, Kahlert UD, Maciaczyk D, Angelsen A, Halgunset J (2012) Changes in gene transcription and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer 110(2):330–340. https://doi.org/10.1038/bjc.2013.709

165. Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson W. Hua et al. 2122

166. Shah T, Wildes F, Penet MF, Winnard PT Jr, Glunde K, Artemov D, Ackerman E, Gimi B, Kakkad S, Raman V, Bhujwalla ZM (2010) Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed 23(6):633–642. https://doi.org/10.1002/nbm.1510

167. Sanford E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramirez de Molina V, Cejas P, Ozu C, Le C, Sanchez JJ, Gonzalez-Baron M, Koutcher J, Cordon-Cardo C, Bochner BH, Lacal JC, Ramirez de Molina A (2009) A critical role for choline kinase-α in the aggressiveness of bladder carcinomas. Oncogene 28(26):2425–2435. https://doi.org/10.1038/onc.2009.91

168. Mondal S, Roy D, Sarkar Bhattacharya S, Jin L, Jung D, Zhang S, Kalogera E, Staub J, Wang Y, Xuyang W, Khurana A, Chien J, Tielan S, Cheyn S, Tapolsky G, Petras D, Shridhar V (2019) Therapeutic targeting of PFKFB3 with a novel glyco-lytic inhibitor PFKF158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer 144(1):178–189. https://doi.org/10.1002/ijc.31868

169. Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson W. Hua et al. 2122

170. Monsal S, Roy D, Sarkar Bhattacharya S, Jin L, Jung D, Zhang S, Kalogera E, Staub J, Wang Y, Xuyang W, Khurana A, Chien J, Tielan S, Cheyn S, Tapolsky G, Petras D, Shridhar V (2019) Therapeutic targeting of PFKFB3 with a novel glyco-lytic inhibitor PFKF158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer 144(1):178–189. https://doi.org/10.1002/ijc.31868

171. Craig D, Logsdon WL, Abbruzzese JL (2013) Cancer metabolism and its therapeutic implications. J Cell Sci Ther 4(2):143. https://doi.org/10.4172/2157-7013.1000143

172. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11):829–846. https://doi.org/10.1038/nrd4145

173. Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson W. Hua et al. 2122

174. Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson W. Hua et al. 2122

175. Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nisticco C, Benetti A, Pini D, Di Lauro R, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P (2003) Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21(18):3462–3468. https://doi.org/10.1200/JCO.2003.03.034

176. Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11):829–846. https://doi.org/10.1038/nrd4145

177. Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11):829–846. https://doi.org/10.1038/nrd4145
L, Vanderbilt A, Williams S, Daemen A, Belvin M, Eigenbrot C, Jackson PK, Malek S, Hatzivassiliou G, Sampath D, Evangelista M, O’Brien T (2016) Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol 12(10):779–786. https://doi.org/10.1038/nchembio.2143

Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99(7):989–994. https://doi.org/10.1038/sj.bjc.6604554

Beloribi-Djefaflia S, Vasseur S, Guillaumond F (2016) Lipid metabolic reprogramming in cancer cells. Oncogenesis 5:e189. https://doi.org/10.1038/oncsis.2015.49

Flavin R, Peluso S, Nguyen PL, Loda M (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6(4):551–562

Menendez JA, Lupu R (2017) Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets 21(11):1001–1016. https://doi.org/10.1080/14728222.2017.1381087

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA (2018) GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 155(5):1463–1473. https://doi.org/10.1053/j.gastro.2018.07.027

Prado-Garcia H, Sanchez-Garcia FJ (2017) Editorial: Immunometabolism in tumor microenvironment. Front Immunol 8:374. https://doi.org/10.3389/fimmu.2017.00374

Yu YR, Ho PC (2019) Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. Clin Exp Immunol 197(2):153–160. https://doi.org/10.1111/cei.13293

Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241. https://doi.org/10.1016/j.cell.2015.08.016

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.